Share on StockTwits

Keryx Biopharmaceuticals (NASDAQ:KERX) CEO Ron Bentsur sold 1,788 shares of the stock in a transaction that occurred on Monday, July 7th. The shares were sold at an average price of $15.75, for a total transaction of $28,161.00. Following the transaction, the chief executive officer now directly owns 876,815 shares of the company’s stock, valued at approximately $13,809,836. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) traded up 1.55% on Wednesday, hitting $15.28. The stock had a trading volume of 1,259,616 shares. Keryx Biopharmaceuticals has a 52 week low of $7.92 and a 52 week high of $17.46. The stock has a 50-day moving average of $14.40 and a 200-day moving average of $14.59. The company’s market cap is $1.397 billion.

Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.15) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.08) by $0.07. The company had revenue of $10.00 million for the quarter, compared to the consensus estimate of $9.91 million. During the same quarter last year, the company posted ($0.03) earnings per share. Keryx Biopharmaceuticals’s revenue was up 42.9% compared to the same quarter last year. Analysts expect that Keryx Biopharmaceuticals will post $-0.79 EPS for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at HC Wainwright reiterated a “buy” rating on shares of Keryx Biopharmaceuticals in a research note on Friday, May 23rd. They now have a $19.00 price target on the stock. Separately, analysts at MLV & Co
cut their price target on shares of Keryx Biopharmaceuticals from $27.00 to $21.00 in a research note on Monday, May 12th. They now have a “buy” rating on the stock. Finally, analysts at Mizuho cut their price target on shares of Keryx Biopharmaceuticals from $34.00 to $32.00 in a research note on Friday, May 9th. Eight analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and a consensus target price of $24.11.

Keryx Biopharmaceuticals, Inc (NASDAQ:KERX) is focused on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.